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A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel 
disease 
Abstract 
The introduction of biological agents has led to significant changes in the treatment of 
inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the 
expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX 
biosimilar approved in the same indications as the reference product, however, the approval 
was based on randomized clinical trials conducted in patients with rheumatoid arthritis and 
ankylosing spondylitis. In the past 2-3 years new findings from prospective observational 
studies supported the short, medium and long-term clinical efficacy and safety of CT-P13 in 
patients with IBD. This review summarized the clinical use and efficacy of the first biosimilar 
IFX, CT-P13, in the treatment of IBD. 
 
Keywords 
infliximab, biosimilar, inflammatory bowel disease 
  
3 
 
Introduction 
The prevalence of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis 
[UC]), a chronic immune-mediated inflammatory gastrointestinal disorders, is continuously 
increasing and places significant burden on the society and healthcare systems worldwide [1]. 
The introduction of biological agents has led to significant changes in the treatment of each 
immune-mediated disorders including IBD and improved the outcomes with the change in the 
natural course of the disease [2]. Infliximab (IFX) was the first biological therapy to be 
approved in IBD and has since been followed by other anti-tumor necrosis factor (TNF) drugs, 
as well as anti-integrin antibodies [3]. Many of the biologicals have recently reached or will 
nearly reach patent expiration. Biosimilars have been introduced with the goals to reduce 
financial burden of biological therapy and extend therapeutic alternatives. The IFX biosimilar 
CT-P13 developed by CELLTRION, Inc, Incheon, South Korea and marketed under the trade 
name Remsima or Inflectra was the first biosimilar licensed for use in IBD in Europe receiving 
approval from the European Medicines Agency (EMA) in September 2013. In April 2016, CT-
P13 was also approved in IBD by the U. S. Food and Drug Administration (FDA). Since then 
increasing knowledge has been collected on the efficacy and safety biosimilar IFX CT-P13.  
Overview of the market 
Anti-TNF α therapies have been introduced more than 15 years ago for the treatment of IBD 
refractory or intolerant to the conventional immunomodulators. In the past few years, use of 
biological therapy became more and more frequent and started earlier than before in order to 
modify disease progression in these chronic conditions. Biological therapies induce mucosal 
healing and sustained clinical remission, decrease the need of hospitalizations and surgery and 
improve the patients’ quality of life [4]. With regaining ability to work, biologicals introduced 
early are important for economic benefits. The ACCENT and ACT studies were the first clinical 
trials in CD and UC confirming the efficacy and safety of the originator IFX in IBD [5, 6]. The 
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ACCENT I trial randomized 573 patients with moderate to severe CD to receive IFX 5 mg/kg, 
IFX 10 mg/kg or placebo at weeks 2 and 6 and every 8 weeks thereafter. Remission rates at 
week 30 and 54 were statistically higher in patients receiving IFX 5 mg/kg and 10 mg/kg 
compared to placebo. In the ACT trials, randomized UC patients receiving originator IFX 5 
mg/kg achieved clinical response at week 8 and 30 in 69.4% and 52.1% of patients in the ACT 
1 and in 64.5% and 47.1% of patients in the ACT 2 studies [6]. In the ACT 1 trial, 45.5% 
maintained clinical response at week 54. The effect of anti TNF therapies in inducing and 
maintaining clinical and endoscopic remission in CD and UC have been further confirmed by 
several studies from the real life. However, the main limitation of using anti-TNF therapies is 
their high price. This and their patent expiration have led to the development of biosimilar 
agents. CT-P13 has been the first monoclonal antibody biosimilar evaluated by EMA.  
 
Introduction to compound 
According to the definition of the EMA, biosimilar is a biological medicinal product that is 
similar to a biological medicine that has already been authorized, the so-called “reference 
medicinal product” [7]. The World Health Organization defines a biosimilar as a 
“biotherapeutic product which is similar in terms of quality, safety and efficacy to an already 
licensed reference biotherapeutic product” [8]. Biosimilars may differ from the original 
reference drug, in particular for post-translational modifications like glycosylation, but 
differences are acceptable if the final molecule falls within defined “boundaries of tolerance”: 
variations in some features of the 2 molecules are only considered important if they are 
clinically relevant [9, 10]. Since biologics are difficult to copy exactly due to their structural 
complexity and the nature of the cell culture systems used in their manufacture, biosimilars are 
highly similar, but not identical to their reference biologics. Therefore comprehensive 
comparability assessment is needed to reveal no clinically important differences are present. 
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Since the efficacy of the reference drug has previously been confirmed, the importance of 
clinical studies regarding to the approval of a biosimilar drug is significantly reduced compared 
to trials required for the approval of the originator. Moreover, biosimilars provide the 
opportunity to pharmaceutical companies to get the authorization for all the indications the 
originator agent has, the so-called “extrapolation” [11]. Requirements for approval of a 
biosimilar by the U.S. FDA, Health Canada and EMA include extensive in vitro studies 
demonstrating similarity to a reference biologic in terms of quality attributes, as well as 
nonclinical and clinical studies demonstrating comparable pharmacokinetics (PK), efficacy, 
safety, and immunogenicity [12]. 
CT-P13 was the first IFX biosimilar approved in the same indications as the reference products 
namely for the treatment of eight autoimmune diseases including rheumatoid arthritis (RA) and 
IBD through extrapolation. The biosimilar IFX CT-P13 and Remicade® have been studied in 
comparative clinical trials conducted in patients with RA [13-15] and ankylosing spondylitis 
(AS) [16-18]. In those studies, the comparison between originator IFX and CT-P13 resulted in 
a strong similarity profile between the two molecules.  
 
Budget impact 
Biosimilars offer discounts versus the originator prices of approximately 20–70%, thus their 
use will probably lead to significant cost savings and increase of access to biological therapy. 
However, the number of published budget impact studies is very limited compared to cost–
effectiveness analyses [19]. A budget impact analysis for the introduction of Remsima across 
the six licensed indications in Germany, the UK, Italy, the Netherlands, and Belgium revealed 
that the annual cost savings resulting from the introduction of Remsima were projected to range 
from €2.89 million to €33.80 million. The cumulative cost savings across the five included 
countries and the six licensed disease areas were projected to range from €25.79 million to 
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€77.37 million [20]. The article by Brodszky et al. aimed to estimate the budget savings that 
can be generated by the use of biosimilar infliximab over the next 3 years in six Central and 
Eastern European countries, namely Bulgaria, the Czech Republic, Hungary, Poland, Romania, 
and Slovakia. According to their results when interchanging between originator and biosimilar 
IFX was not allowed, the introduction of biosimilar IFX resulted in €0.8, 2.6, and 4.5 million 
cost savings. When interchanging was allowed considerably higher budget savings revealed, 
€0.3 million, 7.7, and 8.9 M for the years of 1–3, respectively. Therefore, total cost savings over 
the 3 years were estimated to €8.0 and 16.9 million [19]. 
Pharmacology 
Biologics are defined as active substances derived from living cells or organisms with 
biotechnology methods [21]. The monoclonal antibody IFX is a large (the molecular weight is 
approximately 149,000 Daltons), potentially unstable and immunogenic drug with complex 
three-dimensional structure [22]. For a biosimilar to be approved for the same indications as the 
originator must be comparable in terms of efficacy and safety, have similar immunogenicity 
and be effective for all approved indications. Extrapolation of data from  one indication to 
another is also a pivotal aspect of  biosimilar development. FDA, Health Canada and EMA have 
usually allowed the medical companies to perform extrapolation for all indications, thanks to 
comparability exercises without real clinical data for all indications [12]. During the 
development of CT-P13, comprehensive and extensive assessments of its physicochemical 
characteristics were performed [23]. The primary amino acid sequences of CT-P13 and its 
reference product were confirmed to be the same by several analytical methods [24]. High 
similarities of secondary and higher structures were also demonstrated [25]. However, when 
comparing glycosylation patterns between CT-P13 and the reference product, differences has 
been found in the level of α-fucosylated glycans, implying a potential difference in antibody-
dependent cellular cytotoxicity (ADCC) [23].  
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In vitro studies have demonstrated that CT-P13 and originator IFX have a comparable primary 
pharmacodynamic profile: CT-P13 and IFX reference product showed very similar binding 
affinities for soluble transmembrane TNF α and for the Fcγ receptors. They are also comparable 
regarding to the complement-dependent cytotoxicity and apoptotic effects against a Jurkat T-
cell line expressing TNF α [17]. Some minor differences, including FcγRIIIa receptor binding, 
the level of α-fucosylation and some ADCC have been recorded in comparison with the 
originator IFX in cells overexpressing membrane TNF and by using enriched natural killer cells 
from CD patients with the high-affinity genotypes of the FcR [17]. However, when ADCC 
activity was tested by using whole blood or isolated peripheral blood mononuclear cells, the 
difference in fucosylation for CT-P13 and the innovator drug did not impact ADCC; therefore 
the clinical relevance of the observed difference in FcgRIIIa binding is questionable [26, 27]. 
Pharmacokinetic (PK) equivalence of CT-P13 and IFX reference product has been 
demonstrated in the PLANETRA and PLANETAS studies [13, 17]. PLANETRA was a 
randomized, double-blind, multi-center, parallel-group, Phase III study. The study was 
performed in RA population to demonstrate equivalent efficacy of CT-P13 and the reference 
drug. In the PLANETRA trial, the Cmax and geometric means of both drugs were highly similar. 
PLANETAS was a randomized, double-blind, multi-center, parallel-group, Phase I study 
performed in the AS patient population to demonstrate the PK equivalence of CT-P13 and the 
reference product. The study resulted in similar efficacy and showed that steady state PK was 
equivalent for CT-P13 and the reference product with geometric mean ratios around 100%. 
Secondary PK endpoints including volume of distribution at steady state and terminal 
elimination half-life were also similar [16, 17]. An additional PK trial in healthy individuals 
was thereafter conducted between the European Union–approved and US-approved 
formulations of IFX originators and CT-P13 showed no difference between treatment groups in 
primary PK endpoints [28].  
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Clinical efficacy 
Data on the efficacy and safety of CT-P13 came from the randomized controlled trials in 
rheumatic disease [13-18]. However, it was questionable whether extrapolation of data from 
studies on RA is appropriate for IBD and initially several national societies have raised concerns 
regarding the use of biosimilars in extrapolated indications [12]. Differences in the pathogenesis 
of rheumatic diseases and IBD, the various dosages of IFX and the different mechanism of 
action used in RA and IBD and the concomitant use of methotrexate and CT-P13 in the 
PLANETRA trial suggest that extrapolating data from rheumatology to IBD is not well 
established. Therefore, data from clinical studies on the comparable efficacy were extremely 
important to use biosimilar IFX with convictions in the real life, even if its cost-effectiveness 
compared to the originator is well known [29]. Recently, the overall comparability of CT-P13 
and originator IFX also proved to be well maintained over the longer-term regarding to the 
efficacy, safety and pharmacokinetics. Data of a recently ended phase III randomized controlled 
trial has been presented at the latest congress of the European Crohn’s and Colitis Organisation 
in February, 2017 and at the Digestive Disease Week congress in May 2017 [30, 31]. In the 
study 220 patients with CD were examined whether CT-P13 is comparable to reference IFX as 
determined by the Crohn’s Disease Activity Index (CDAI), a measurement used to quantify the 
symptoms of CD patients. According to the 6 week data, similar clinical remission, CDAI-70 
and CDAI-100 response rates were observed in both CT-P13 and reference IFX treatment 
groups [31]. A recently completed phase III study aimed to demonstrate non-inferiority in 
efficacy and to assess overall safety of CT-P13 compared with Remicade in patients with active 
CD and to assess efficacy of biosimilar IFX compared with the originator compound in CD and 
UC patients in remission under treatment with IFX for up to 3 months [32].  
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Postmarketing study 
Post-marketing studies had crucial role to provide deeper insights into the efficacy and safety 
of CT-P13 therapy and to support its use in IBD patients. However, in most of these studies 
clinical efficacy was evaluated with using clinical activity scores being less sensitive than in 
vitro testing of comparability. Among the first real life experiences, a case series published by 
Kang et al. revealed clinical response and remission at 8 weeks to be 87.5 % in case of CT-P13 
treatment of IFX naive patients. However, sample size was too small to allow statistical 
comparisons between the clinical efficacy, safety, and interchangeability of CT-P13 [33]. Jung 
et al. revealed clinical response and remission rates in anti-TNF naive CD patients in 90.6% 
and 84.4% at week 8, 95.5% and 77.3% at week 30, and 87.5% and 75.0% at week 54 [34]. In 
anti-TNF naive UC patients, rates of clinical response and remission were 81.0% and 38.1% at 
week 8, 91.3% and 47.8% at week 30, and 100% and 50.0% at week 54, respectively, while 
mucosal healing rates were 58.3% at week 8, 66.7% at week 30, and 66.7% at week 54. The 
efficacy of CT-P13 was maintained in 92.6% of CD and 66.7% of UC patients after switching 
from the originator to the biosimilar IFX [33]. Safety and efficacy at week 14 and 30 of CT-
P13 had been confirmed in an open-label, retrospective, multicenter postmarketing study by 
Park et al. with remission rates of 69.2% and 59.0% in CD and 49.1% and 37% in UC [35]. The 
study was not powered to evaluate efficacy. The first European data came from Hungary in an 
observational, prospective study performed by our workgroup with the enrollment of 39 IBD 
patients showed an overall clinical response and remission rates at week 8 in 37.5% (partial 
response) and 50% of CD patients and in 20 and 66.7% of UC patients [36]. A prospective, 
observational study from the Czech Republic confirmed the short term efficacy of CT-P13 
therapy at week 14 in 52 IBD patients with response and remission rates of 50-50% in CD and 
54.5-40.9% in UC [37]. The study by Sieczkowska-Golub et al. also confirmed that the 
induction therapy with CT-P13 is effective in children with CD [38]. A Hungarian prospective, 
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multicenter, observational study evaluating 210 IBD patients showed CT-P13 to be highly 
effective in inducing and maintaining clinical remission and response in both CD and UC 
patients up to week 30 with response and remission rates of 81.4% and 53.6% of CD and 77.6% 
and 58.6% of UC patients at week 14. At Week 30, 67.2% of week 14 responder CD patients 
maintained clinical response to CT-P13 and 53.4% were in clinical remission. In UC, at week 
30, 80% of week 14 responder patients maintained clinical response to CT-P13 and 68% of the 
patients were in clinical remission [39]. A prospective observational study performed in a single 
center in Norway showed that 79% of CD and 56% of UC patients achieved remission at week 
14 [40]. Argüelles-Arias F et al. showed that 87.5 and 83.9% of CD patients switched from 
reference IFX to CT-P13 who was in remission at the time of the switch continued in remission, 
and 66.7 and 50% of naive CD patients reached remission, at months 3 and 6. In UC switched 
cases, 92 and 91.3% of patients in remission at the time of the switch continued in remission, 
at 3 and 6 months. In naive UC patients, the remission rates were 44.4 and 66.7%, at months 3 
and 6 [41]. 
Mucosal healing after induction therapy was evaluated at first by our workgroup showing rate 
of mucosal healing to be 60.3% of the enrolled UC patients with complete mucosal healing in 
27% of them at week 14 [42]. The recently published PROSIT-BIO study is the largest cohort 
of IBD patients treated with CT-P13 so far. The study evaluated the efficacy of CT-P13 in 434 
patients who received treatment for at least 8 weeks. 8.1% of the patients were primary failures. 
After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for 
naive; 97.2%, 85.2%, and 62.2% for pre-exposed to anti-TNF α; and 94.5%, 90.8%, and 78.9% 
for switch [43]. However, this study was not powered to discover potential differences of 
efficacy based on duration of withdrawal, disease activity, and use of combination therapy at 
the time of starting treatment with the biosimilar. The effects of switching to CT-P13 from 
reference IFX have been investigated in a Polish study including 39 pediatric IBD patients. In 
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the CD group, 69% were in remission at the time of switching. As a limitation of the study, time 
of switching to IFX biosimilar during the course of therapy was heterogeneous and no data was 
available about trough levels or anti-drug antibody levels before switching. After a further mean 
follow-up period of 8 months, 88% of the patients remained in clinical remission [44]. In the 
prospective, observational study by Smits et al 83 IBD patients treated with the originator IFX 
was switched to the biosimilar agent and were followed up until 16 weeks. They found that 
switching did not result in significant changes of disease activity [45]. The 12-month results 
revealed clinical remission rates of 64% at baseline and 73% at week 52 [46]. In the study by 
Buer et al. 143 IBD patients were switched from Remicade to Remsima®. Throughout follow-
up 97% of the patients remained on Remsima®. No significant changes in disease activity were 
observed after the switch from the originator to the biosimilar IFX [47]. In the study by 
Razanskaite V et al. patient outcomes assessed by the IBD-control Patient-Reported Outcome 
Measures questionnaire showed an improvement in IBD control-8 score after the switch to CT-
P13 [48]. 
The largest study evaluating the efficacy and safety of switching from the originator to the 
biosimilar IFX is NOR-SWITCH, a randomised, phase IV, double-blind, parallel-group study 
that showed that switching from IFX originator to CT-P13 was not inferior to continued 
treatment with IFX originator. The study was a non-inferiority trial enrolling 482 patients with 
RA, spondyloarthritis, psoriatic arthritis, UC, CD, and chronic plaque psoriasis and followed 
for 52 weeks. Patients were randomised 1:1 to either continue originator IFX or switch to CT-
P13 treatment using an unchanged dosing regimen. One hundred fifty-five patients in the full 
analysis set had CD, 93 had UC. However, the efficacy analysis consisted of the total eligible 
randomized patients who were switched from the originator IFX to CT-P13. Considering the 
total population, disease worsening occurred in 26% and 30% of patients in the originator and 
CT-P13 arms. The incidence of anti-drug antibodies detected during the study was 7% and 8% 
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in the originator and CT-P13 patients [49]. The findings of the NOR-SWITCH trial suggest that 
patients can be switched from originator IFX to biosimilar IFX which could substantially affect 
the use of CT-P13 and health budgets in many countries. However, the study was not powered 
to show non-inferiority in individual diseases. The recently published study from the Czech 
Republic enrolled 74 IBD patients, who were switched to biosimilar from originator and 119 
naive patients newly initiated therapy with the CT-P13. Disease activity remained stable in a 
majority of switched patients (remission at week 0 vs. week 56: 72.2 vs.77.8%). Overall, 
response rates at week 14 were 92% of CD and 83% of UC patients, while response rates at 
week 46 were 86% in CD and 64% in UC. Half of UC patients experienced mucosal healing at 
week 14 and improvement of perianal disease occurred in 95% of CD at week 46 [50]. Data on 
long-term efficacy is limited regarding CT-P13 use in IBD. According to our unpublished data, 
remission rates at week 54 were 62% in CD and 65% in UC patients treated with CT-P13 [51]. 
Table 1 contains a summary of the postmarketing studies relating on the short, medium and 
long-term clinical efficacy of CT-P13 in CD and UC. 
 
Safety and tolerability 
The first position statement of ECCO on the use of biosimilars in the treatment of IBD was 
published in 2013 and raised some cautions on the use of biosimilars [52]. In an anonymous 
survey, only 24% of ECCO respondents stated that a biologic medication should be able to be 
approved through disease extrapolation to other disease. Sixty-seven % of IBD specialists 
named immunogenicity as their main concern therefore ECCO called for more data on the safety 
and benefit of biosimilars [53]. According to an online survey conducted among patients by 
Peyrin-Biroulet et al. 38% had heard about biosimilars. Only 25.2% of the respondents had no 
concerns about them. Forty-seven % of the responders worried about biosimilars’ safety profile, 
40.3% about the efficacy and 35% about the molecular basis. The survey also revealed that 
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20.9% of the respondents would be against the idea of interchangeability if the patient was not 
aware [54]. A second survey amongst ECCO members in 2016 reflected a major changing 
regarding biosimilar use and 28.8% of survey respondents reported they were ‘totally confident’ 
prescribing biosimilar medications compared to 5% according to the previous survey [55]. The 
updated ECCO position statement showed a significant shift in attitude from the previous one 
and agreed on that switching from the originator to a biosimilar in patients with IBD is 
acceptable and adverse events and loss of response cannot be expected to be overcome with a 
biosimilar of the same molecule [56]. Data on safety and tolerability coming from the real life 
studies had main importance in the acceptance of CT-P13 in the treatment of IBD. In the 
PLANETRA trial conducted in RA patients, treatment-emergent adverse events (TEAEs) were 
reported in 35.2% and 35.9% of the subjects. Regarding immunogenicity, anti-drug antibodies 
(ADAs) were detected in comparable proportions of patients receiving CT-P13 (25.4 and 
48.4%) and reference product (25.8 and 48.2%) at weeks 14 and 30 and overall, CT-P13 and 
originator IFX had similar safety profiles. TEAEs were reported in 60.1% and 60.8% of patients 
receiving CT-P13 and reference drug [13]. In the PLANETAS study adverse events in the CT-
P13 and IFX originator groups were reported in 64.8% and 63.9% of the subjects, respectively, 
while infusion reactions occurred in 3.9% and 4.9% of the cases. In the CT-P13 group, ADAs 
were detected in 9.1% and 27.4% of patients at weeks 14 and 30, respectively. In the reference 
drug group, ADAs were detected in 11% and 22.5% of the patients at weeks 14 and 30 [17]. 
The cross-immunogenicity of the biosimilar IFX Remsima® with the originator drug Remicade 
has been examined in the study published by Ben-Horin et al. [57]. All 69 positive anti-
Remicade IBD sera were shown to be cross-reactive with Remsima. Anti-Remicade antibodies 
inhibit similarly Remsima and Remicade TNF-α binding capacity. Regarding to IBD studies, 
Park et al. revealed TEAEs in 10% of the enrolled IBD patients being mainly mild-to-moderate 
in severity [35]. Our study of 18 CD and 21 UC patients revealed a mild arthralgia in 1 CD 
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patients and an anaphylactic reaction after the second infusion of CT-P13 in a UC patient with 
high ADA levels and previously treated with the originator IFX [36]. In the Norwegian study 
by Jahnsen et al., infusion reaction occurred in 1 CD and 1 UC patients, rate of adverse event 
was 2.2% and 3.1% in CD and UC [40]. The studies from Poland revealed that safety profile is 
similar to that reported for the reference IFX and adverse event rate did not differ significantly 
either in CD or in UC before and after the switch from IFX to CT-P13 [38, 44]. The Hungarian 
multicenter study revealed adverse events in 17.1% of all patients. Infusion reactions occurred 
in 6.7% of CT-P13 treated patients, 71.4% of them had previously received the originator IFX. 
Infusion reactions occurred in a significantly higher proportion of patients with previous IFX 
exposure compared with naive patients [39]. Smits et al published adverse events in 29% of the 
patients after switching [45]. The study by Buer et al. revealed adverse events in 6.8% of UC 
and 14% of CD patients after switching to the biosimilar IFX. Rate of infusion reaction was 
0.7% [47]. In the PROSIT-BIO cohort, serious adverse events were reported in 12.1% of the 
IBD patients, 6.9% of them were infusion-related reactions [43]. However, infusion reactions 
were significantly more frequent in patients pre-exposed to infliximab than to other anti TNF-
α. The NOR-SWITCH study revealed an incidence of ADAs as being 7% and 8% in the 
originator and CT-P13 patients, respectively. The frequency of adverse events was similar 
between groups: for serious adverse events, 10% for IFX originator vs. 9% for CT-P13; for 
overall adverse events, 70% vs. 68%; and for adverse events leading to discontinuation, 4% vs. 
3%, respectively [49]. The multicenter, prospective study examining the rate, the characteristics 
and the predictors of infusion reactions developed in CT-P13-treated Hungarian and Czech IBD 
patients revealed infusion reactions to occur in 7.3% of all the enrolled patients. 35.7% of 
patients developing infusion reaction were anti TNF naive. Anti-CT-P13 antibody was proved 
in 32.6% of patients with infusion reaction and 4.1% of subjects without any reaction during 
treatment. Our results suppose a lower immunogenicity of the biosimilar in CD and similar rates 
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and characteristics of infusion reaction with the originator [58]. Table 1 contains a summary of 
the postmarketing studies relating on the safety profile of CT-P13 in CD and UC. 
 
Regulatory affairs 
IFX biosimilar was approved by the EMA under the trade name Remsima® in September 2013 
and launched in Europe in early 2015. The US FDA approved Celltrion’s CT-P13 in April 2016 
under the trade name Inflectra™. CT-P13 is now approved in more than 79 (as of January 2017) 
countries including the US, Canada, Japan and throughout Europe [59]. In May 2016 SB2 
(Flixabi®) was the second biosimilar to infliximab receiving marketing authorization in Europe. 
The efficacy of SB2 was evaluated in a randomized double-blind, multinational phase III trial 
in adult patients with moderate to severe rheumatoid arthritis despite methotrexate therapy [60]. 
During the 24-week switching period of the study efficacy was sustained as indicated by similar 
response rates across treatment groups [61]. Currently, >20 other biosimilars to infliximab and 
adalimumab are in the development pipeline. Generally, clinicians need to decide about 
switching from the reference biologic agent to a biosimilar. However, in the future, they will 
probably need to also consider a switch in the opposite direction (reverse-switch), or from one 
biosimilar to another (cross-switch) which may express concerns about the interchangeability 
if the drugs in this form [62]. The follow-up study of NOR-SWITCH will add useful 
information about the safety and efficacy of reverse-switch. 
 
Conclusion 
Biosimilars represent an opportunity to reduce healthcare costs and increase access to 
biologicals in several countries. Cost savings associated with the use of CT-P13 across all 
indications were studied in five European countries from the beginning of 2015 to the first half 
of 2016. According to the data presented at the 12th Congress of ECCO, total cost savings 
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observed for Germany, Italy, Spain and the UK amounted to €32.4 million and the findings 
suggest that this could allow an additional 5,428 patients a year access to this important biologic 
therapy. There were no cost savings in France, as the price of biosimilar and reference IFX were 
the same, however despite this; use of CT-P13 has gradually increased in this country [63]. As 
access to biologicals, these highly effective therapeutic options broaden, the wider they will be 
used and as their significant clinical benefits, more patients will be able to receive more 
effective therapy earlier in their disease. The changes in the current pyramidal paradigm of 
therapy will give way to individualized therapeutic planning. 
 
Executive summary 
The introduction of biological agents has led to significant changes in the treatment of IBD with 
improving the outcomes of the patients. The relatively high price of IFX, the first biological 
therapy approved in IBD, and the expiration of the patents led to the introduction of biosimilar 
agents. 
Introduction to compound 
CT-P13 was the first IFX biosimilar approved in the same indications as the reference products. 
The approval of the biosimilar IFX was based on randomized clinical trials conducted in 
patients with RA and AS. 
Pharmacokinetic properties 
PK equivalence of CT-P13 and IFX reference product has been first demonstrated in AS and 
RA patients. An additional PK trial in healthy individuals showed no difference thereafter 
between the European Union–approved and US-approved formulations of IFX originators and 
CT-P13 treatment groups in primary PK endpoints. 
Efficacy and safety profile 
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Efficacy and safety of CT-P13 has been initially evaluated in rheumatologic diseases, where it 
has demonstrated its equivalency in terms of efficacy and safety compared to the original IFX. 
However, in the past 2-3 years, many data have raised from prospective observational studies 
supporting the short, medium and long-term clinical efficacy and safety of CT-P13 in patients 
with IBD, including those who switched from the originator IFX. 
Regulatory affairs 
IFX biosimilar was approved by the EMA under the trade name Remsima® in September 2013 
and launched in Europe in early 2015. The US FDA approved Celltrion’s CT-P13 in April 2016 
under the trade name Inflectra™. 
Conclusion 
The biosimilar IFX CT-P13 is already available in many countries for IBD. Clinical studies did 
not find significant difference in terms of efficacy, safety and immunogenicity of CT-P13 in 
IBD, moreover, switching of IBD patients from original to biosimilar IFX also proved to be 
effective and safe. The increasing number of publications on the biosimilar medications in IBD 
will support the use of CT-P13 in this indication in patients who may not have been able to 
afford biologic therapy previously. 
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